Receptor T-Cell Chimeric Antigen Approach Used for the Prediction Model Treatment for Relapsed/Refractory Multiple Myeloma

被引：1

作者：

Yin, Zhao ^{[1
]}

Zhang, Qing ^{[1
]}

Ou, Ruiming ^{[1
]}

Liu, Shuang ^{[1
]}

机构：

[1] Guangdong Second Prov Gen Hosp, Dept Hematol, Guangzhou, Peoples R China

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 25期

关键词：

D O I：

10.1200/JCO.24.00544

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[41] Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Chari, Ajai
Vogl, Dan T.
Jagannath, Sundar
Jasielec, Jagoda K.
DeCastro, Andrew
Unger, Tj
Shah, Jatin
Jakubowiak, Andrzej
BLOOD, 2019, 134
[42] Comprehensive characterization of cytopenia after chimeric antigen receptor-T cell infusion in patients with relapsed or refractory multiple myeloma
Cheng, Hai
Shao, Lingyan
Wang, Dandan
Chen, Yegan
Sun, Yingjun
Chen, Zihan
Liu, Jiaying
Wang, Xue
Chen, Wei
Sang, Wei
Qi, Kunming
Li, Zhenyu
Sun, Cai
Shi, Ming
Qiao, Jianlin
Wu, Qingyun
Zeng, Lingyu
Zheng, Junnian
Li, Li
Xu, Kailin
Cao, Jiang
CYTOTHERAPY, 2025, 27 (01) : 16 - 24
[43] Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
Hu, Hongxiang
Li, Yan
Piasecki, Julia
Hosseyni, Daniela
Yan, Zhicheng
Liu, Xianghong
Ogasawara, Ken
Zhou, Simon
Cheng, Yiming
CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1163 - 1171
[44] Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Yamamoto, Chihiro
Minakata, Daisuke
Yokoyama, Daizo
Furuki, Shuka
Noguchi, Atsuto
Koyama, Shunsuke
Oyama, Takashi
Murahashi, Rui
Nakashima, Hirotomo
Ikeda, Takashi
Kawaguchi, Shin-ichiro
Hyodo, Kazuki
Toda, Yumiko
Ito, Shoko
Nagayama, Takashi
Umino, Kento
Morita, Kaoru
Ashizawa, Masahiro
Ueda, Masuzu
Hatano, Kaoru
Sato, Kazuya
Ohmine, Ken
Fujiwara, Shin-ichiro
Kanda, Yoshinobu
TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 118.e1 - 118.e15
[45] Paving the Way toward Successful Multiple Myeloma Treatment: Chimeric Antigen Receptor T-Cell Therapy
Grywalska, Ewelina
Sosnowska-Pasiarska, Barbara
Smok-Kalwat, Jolanta
Pasiarski, Marcin
Niedzwiedzka-Rystwej, Paulina
Rolinski, Jacek
CELLS, 2020, 9 (04)
[46] B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis
Gagelmann, Nico
Ayuk, Francis
Atanackovic, Djordje
Kroeger, Nicolaus
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (04) : 318 - 327
[47] CAR T-cell therapy for relapsed or refractory multiple myeloma
Stirrups, Robert
LANCET ONCOLOGY, 2019, 20 (06): : E297 - E297
[48] Chimeric Antigen Receptor T Cells for the Treatment of Multiple Myeloma
Testa, Ugo
Pelosi, Elvira
Castelli, Germana
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2024, 16 (01)
[49] Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
Hasanali, Zainul S.
Razzo, Beatrice
Susanibar-Adaniya, Sandra P.
Garfall, Alfred L.
Stadtmauer, Edward A.
Cohen, Adam D.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2024, 38 (02) : 383 - 406
[50] Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma
Lebel, Eyal
Kfir-Erenfeld, Shlomit
Asherie, Nathalie
Grisariu, Sigal
Avni, Batia
Elias, Shlomo
Assayag, Miri
Dubnikov, Tatyana
Zalcman, Nomi
Pick, Marjorie
Zimran, Eran
Shaulov, Adir
Cohen, Yael
Avivi, Irit
Cohen, Cyrille
Stepensky, Polina
Gatt, Moshe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S47 - S48

← 1 2 3 4 5 →